author_facet Mullally, Ann
Bruedigam, Claudia
Heckl, Dirk
Poveromo, Luke
Heidel, Florian H.
Hill, Geoff
Ebert, Benjamin L.
Lane, Steven W.
Mullally, Ann
Bruedigam, Claudia
Heckl, Dirk
Poveromo, Luke
Heidel, Florian H.
Hill, Geoff
Ebert, Benjamin L.
Lane, Steven W.
author Mullally, Ann
Bruedigam, Claudia
Heckl, Dirk
Poveromo, Luke
Heidel, Florian H.
Hill, Geoff
Ebert, Benjamin L.
Lane, Steven W.
spellingShingle Mullally, Ann
Bruedigam, Claudia
Heckl, Dirk
Poveromo, Luke
Heidel, Florian H.
Hill, Geoff
Ebert, Benjamin L.
Lane, Steven W.
Blood
Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera
Cell Biology
Hematology
Immunology
Biochemistry
author_sort mullally, ann
spelling Mullally, Ann Bruedigam, Claudia Heckl, Dirk Poveromo, Luke Heidel, Florian H. Hill, Geoff Ebert, Benjamin L. Lane, Steven W. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v120.21.806.806 <jats:title>Abstract</jats:title> <jats:p>Abstract 806</jats:p> <jats:p>Interferon alpha (IFNα) is an effective treatment for patients with myeloproliferative neoplasms (MPN). In addition to inducing hematological responses in most MPN patients, IFNα reduces the JAK2V617F allelic burden and can render the JAK2V617F mutant clone undetectable in some patients. The mechanism underlying these responses is incompletely understood and whether the molecular responses that are seen occur due to the effects of IFNα on JAK2V617F mutant stem cells is debated.</jats:p> <jats:p>Using a murine model of Jak2V617F MPN, we investigated the effects of IFNα on Jak2V617F MPN stem cells in vivo. Chimeric transplant recipients were generated with purified stem cell enriched populations (lin−Kit+Sca1+) and these were treated for 4 weeks with either IFNα or vehicle control.</jats:p> <jats:p>IFNα treatment caused a reduction in extramedullary hematopoiesis (spleen weight, vehicle 262mg vs IFNα 192mg, p&lt;0.01), hematocrit (vehicle 76.0% vs IFNα 65.5%, p&lt;0.05) and white blood cell count (vehicle 13.9×109/L vs IFNα 7.5×109/L, p&lt;0.01) in this disease model. IFNα treatment caused a reduction in early (CD71+Ter119+) erythroid progenitors that had accumulated in the spleen of Jak2V617F mice. IFNα treatment caused selective depletion of Jak2V617F MPN hematopoietic stem cells (HSC, lin−kit+Sca1+CD150+CD48−) over time and this was associated with reduced Jak2V617F chimerism in the long-term HSC compartment (Jak2V617F chimerism Vehicle 41.4% vs. IFNα 23.9%, p&lt;0.05). IFNα treatment impaired the transmission of Jak2V617F-MPN and reduced Jak2V617F chimerism in transplanted recipient mice, demonstrating functional depletion of disease-specific stem cells.</jats:p> <jats:p>Mechanistically, IFNα treatment preferentially induced cell-cycle activation of Jak2V617F mutant long-term HSCs. Gene expression profiling revealed relative enrichment of cell cycle genes and depletion of quiescence related genes in IFNα treated Jak2V617F HSC compared to IFNα treated WT HSC. IFNα treatment promoted a predetermined terminal erythroid-lineage differentiation program within myeloid progenitor cells. The effects on Jak2V617F long-term HSC were absent in Jak2V617F+/−IFNAR1−/− (lacking the type 1 interferon receptor) chimeric mice demonstrating that the effects of IFNα treatment were cell autonomous and specific for type 1 interferon signalling.</jats:p> <jats:p>These findings provide insights into the differential effects of IFNα on Jak2V617F mutant and normal hematopoiesis and suggest that IFNα achieves molecular remissions in MPN patients through its effects on MPN stem cells. Furthermore, these results support combinatorial therapeutic approaches in MPN, by concurrently depleting dormant JAK2V617F MPN-propagating stem cells with IFNα and targeting the proliferating downstream progeny with JAK2-inhibitors or cytotoxic chemotherapy.</jats:p> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>Heidel: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees. Ebert:Celgene: Consultancy; Genoptix: Consultancy.</jats:p> </jats:sec> Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera Blood
doi_str_mv 10.1182/blood.v120.21.806.806
facet_avail Online
Free
finc_class_facet Biologie
Medizin
Chemie und Pharmazie
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTIwLjIxLjgwNi44MDY
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTIwLjIxLjgwNi44MDY
institution DE-Bn3
DE-Brt1
DE-D161
DE-Zwi2
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
imprint American Society of Hematology, 2012
imprint_str_mv American Society of Hematology, 2012
issn 0006-4971
1528-0020
issn_str_mv 0006-4971
1528-0020
language English
mega_collection American Society of Hematology (CrossRef)
match_str mullally2012depletionofjak2v617fmpnstemcellsbyifnainamurinemodelofpolycythemiavera
publishDateSort 2012
publisher American Society of Hematology
recordtype ai
record_format ai
series Blood
source_id 49
title Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera
title_unstemmed Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera
title_full Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera
title_fullStr Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera
title_full_unstemmed Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera
title_short Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera
title_sort depletion of jak2v617f mpn stem cells by ifnα in a murine model of polycythemia vera
topic Cell Biology
Hematology
Immunology
Biochemistry
url http://dx.doi.org/10.1182/blood.v120.21.806.806
publishDate 2012
physical 806-806
description <jats:title>Abstract</jats:title> <jats:p>Abstract 806</jats:p> <jats:p>Interferon alpha (IFNα) is an effective treatment for patients with myeloproliferative neoplasms (MPN). In addition to inducing hematological responses in most MPN patients, IFNα reduces the JAK2V617F allelic burden and can render the JAK2V617F mutant clone undetectable in some patients. The mechanism underlying these responses is incompletely understood and whether the molecular responses that are seen occur due to the effects of IFNα on JAK2V617F mutant stem cells is debated.</jats:p> <jats:p>Using a murine model of Jak2V617F MPN, we investigated the effects of IFNα on Jak2V617F MPN stem cells in vivo. Chimeric transplant recipients were generated with purified stem cell enriched populations (lin−Kit+Sca1+) and these were treated for 4 weeks with either IFNα or vehicle control.</jats:p> <jats:p>IFNα treatment caused a reduction in extramedullary hematopoiesis (spleen weight, vehicle 262mg vs IFNα 192mg, p&lt;0.01), hematocrit (vehicle 76.0% vs IFNα 65.5%, p&lt;0.05) and white blood cell count (vehicle 13.9×109/L vs IFNα 7.5×109/L, p&lt;0.01) in this disease model. IFNα treatment caused a reduction in early (CD71+Ter119+) erythroid progenitors that had accumulated in the spleen of Jak2V617F mice. IFNα treatment caused selective depletion of Jak2V617F MPN hematopoietic stem cells (HSC, lin−kit+Sca1+CD150+CD48−) over time and this was associated with reduced Jak2V617F chimerism in the long-term HSC compartment (Jak2V617F chimerism Vehicle 41.4% vs. IFNα 23.9%, p&lt;0.05). IFNα treatment impaired the transmission of Jak2V617F-MPN and reduced Jak2V617F chimerism in transplanted recipient mice, demonstrating functional depletion of disease-specific stem cells.</jats:p> <jats:p>Mechanistically, IFNα treatment preferentially induced cell-cycle activation of Jak2V617F mutant long-term HSCs. Gene expression profiling revealed relative enrichment of cell cycle genes and depletion of quiescence related genes in IFNα treated Jak2V617F HSC compared to IFNα treated WT HSC. IFNα treatment promoted a predetermined terminal erythroid-lineage differentiation program within myeloid progenitor cells. The effects on Jak2V617F long-term HSC were absent in Jak2V617F+/−IFNAR1−/− (lacking the type 1 interferon receptor) chimeric mice demonstrating that the effects of IFNα treatment were cell autonomous and specific for type 1 interferon signalling.</jats:p> <jats:p>These findings provide insights into the differential effects of IFNα on Jak2V617F mutant and normal hematopoiesis and suggest that IFNα achieves molecular remissions in MPN patients through its effects on MPN stem cells. Furthermore, these results support combinatorial therapeutic approaches in MPN, by concurrently depleting dormant JAK2V617F MPN-propagating stem cells with IFNα and targeting the proliferating downstream progeny with JAK2-inhibitors or cytotoxic chemotherapy.</jats:p> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>Heidel: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees. Ebert:Celgene: Consultancy; Genoptix: Consultancy.</jats:p> </jats:sec>
container_issue 21
container_start_page 806
container_title Blood
container_volume 120
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792323811098492934
geogr_code not assigned
last_indexed 2024-03-01T11:39:44.063Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Depletion+of+Jak2V617F+MPN+Stem+Cells+by+IFN%CE%B1+in+a+Murine+Model+of+Polycythemia+Vera&rft.date=2012-11-16&genre=article&issn=1528-0020&volume=120&issue=21&spage=806&epage=806&pages=806-806&jtitle=Blood&atitle=Depletion+of+Jak2V617F+MPN+Stem+Cells+by+IFN%CE%B1+in+a+Murine+Model+of+Polycythemia+Vera&aulast=Lane&aufirst=Steven+W.&rft_id=info%3Adoi%2F10.1182%2Fblood.v120.21.806.806&rft.language%5B0%5D=eng
SOLR
_version_ 1792323811098492934
author Mullally, Ann, Bruedigam, Claudia, Heckl, Dirk, Poveromo, Luke, Heidel, Florian H., Hill, Geoff, Ebert, Benjamin L., Lane, Steven W.
author_facet Mullally, Ann, Bruedigam, Claudia, Heckl, Dirk, Poveromo, Luke, Heidel, Florian H., Hill, Geoff, Ebert, Benjamin L., Lane, Steven W., Mullally, Ann, Bruedigam, Claudia, Heckl, Dirk, Poveromo, Luke, Heidel, Florian H., Hill, Geoff, Ebert, Benjamin L., Lane, Steven W.
author_sort mullally, ann
container_issue 21
container_start_page 806
container_title Blood
container_volume 120
description <jats:title>Abstract</jats:title> <jats:p>Abstract 806</jats:p> <jats:p>Interferon alpha (IFNα) is an effective treatment for patients with myeloproliferative neoplasms (MPN). In addition to inducing hematological responses in most MPN patients, IFNα reduces the JAK2V617F allelic burden and can render the JAK2V617F mutant clone undetectable in some patients. The mechanism underlying these responses is incompletely understood and whether the molecular responses that are seen occur due to the effects of IFNα on JAK2V617F mutant stem cells is debated.</jats:p> <jats:p>Using a murine model of Jak2V617F MPN, we investigated the effects of IFNα on Jak2V617F MPN stem cells in vivo. Chimeric transplant recipients were generated with purified stem cell enriched populations (lin−Kit+Sca1+) and these were treated for 4 weeks with either IFNα or vehicle control.</jats:p> <jats:p>IFNα treatment caused a reduction in extramedullary hematopoiesis (spleen weight, vehicle 262mg vs IFNα 192mg, p&lt;0.01), hematocrit (vehicle 76.0% vs IFNα 65.5%, p&lt;0.05) and white blood cell count (vehicle 13.9×109/L vs IFNα 7.5×109/L, p&lt;0.01) in this disease model. IFNα treatment caused a reduction in early (CD71+Ter119+) erythroid progenitors that had accumulated in the spleen of Jak2V617F mice. IFNα treatment caused selective depletion of Jak2V617F MPN hematopoietic stem cells (HSC, lin−kit+Sca1+CD150+CD48−) over time and this was associated with reduced Jak2V617F chimerism in the long-term HSC compartment (Jak2V617F chimerism Vehicle 41.4% vs. IFNα 23.9%, p&lt;0.05). IFNα treatment impaired the transmission of Jak2V617F-MPN and reduced Jak2V617F chimerism in transplanted recipient mice, demonstrating functional depletion of disease-specific stem cells.</jats:p> <jats:p>Mechanistically, IFNα treatment preferentially induced cell-cycle activation of Jak2V617F mutant long-term HSCs. Gene expression profiling revealed relative enrichment of cell cycle genes and depletion of quiescence related genes in IFNα treated Jak2V617F HSC compared to IFNα treated WT HSC. IFNα treatment promoted a predetermined terminal erythroid-lineage differentiation program within myeloid progenitor cells. The effects on Jak2V617F long-term HSC were absent in Jak2V617F+/−IFNAR1−/− (lacking the type 1 interferon receptor) chimeric mice demonstrating that the effects of IFNα treatment were cell autonomous and specific for type 1 interferon signalling.</jats:p> <jats:p>These findings provide insights into the differential effects of IFNα on Jak2V617F mutant and normal hematopoiesis and suggest that IFNα achieves molecular remissions in MPN patients through its effects on MPN stem cells. Furthermore, these results support combinatorial therapeutic approaches in MPN, by concurrently depleting dormant JAK2V617F MPN-propagating stem cells with IFNα and targeting the proliferating downstream progeny with JAK2-inhibitors or cytotoxic chemotherapy.</jats:p> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>Heidel: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees. Ebert:Celgene: Consultancy; Genoptix: Consultancy.</jats:p> </jats:sec>
doi_str_mv 10.1182/blood.v120.21.806.806
facet_avail Online, Free
finc_class_facet Biologie, Medizin, Chemie und Pharmazie
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTIwLjIxLjgwNi44MDY
imprint American Society of Hematology, 2012
imprint_str_mv American Society of Hematology, 2012
institution DE-Bn3, DE-Brt1, DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275
issn 0006-4971, 1528-0020
issn_str_mv 0006-4971, 1528-0020
language English
last_indexed 2024-03-01T11:39:44.063Z
match_str mullally2012depletionofjak2v617fmpnstemcellsbyifnainamurinemodelofpolycythemiavera
mega_collection American Society of Hematology (CrossRef)
physical 806-806
publishDate 2012
publishDateSort 2012
publisher American Society of Hematology
record_format ai
recordtype ai
series Blood
source_id 49
spelling Mullally, Ann Bruedigam, Claudia Heckl, Dirk Poveromo, Luke Heidel, Florian H. Hill, Geoff Ebert, Benjamin L. Lane, Steven W. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v120.21.806.806 <jats:title>Abstract</jats:title> <jats:p>Abstract 806</jats:p> <jats:p>Interferon alpha (IFNα) is an effective treatment for patients with myeloproliferative neoplasms (MPN). In addition to inducing hematological responses in most MPN patients, IFNα reduces the JAK2V617F allelic burden and can render the JAK2V617F mutant clone undetectable in some patients. The mechanism underlying these responses is incompletely understood and whether the molecular responses that are seen occur due to the effects of IFNα on JAK2V617F mutant stem cells is debated.</jats:p> <jats:p>Using a murine model of Jak2V617F MPN, we investigated the effects of IFNα on Jak2V617F MPN stem cells in vivo. Chimeric transplant recipients were generated with purified stem cell enriched populations (lin−Kit+Sca1+) and these were treated for 4 weeks with either IFNα or vehicle control.</jats:p> <jats:p>IFNα treatment caused a reduction in extramedullary hematopoiesis (spleen weight, vehicle 262mg vs IFNα 192mg, p&lt;0.01), hematocrit (vehicle 76.0% vs IFNα 65.5%, p&lt;0.05) and white blood cell count (vehicle 13.9×109/L vs IFNα 7.5×109/L, p&lt;0.01) in this disease model. IFNα treatment caused a reduction in early (CD71+Ter119+) erythroid progenitors that had accumulated in the spleen of Jak2V617F mice. IFNα treatment caused selective depletion of Jak2V617F MPN hematopoietic stem cells (HSC, lin−kit+Sca1+CD150+CD48−) over time and this was associated with reduced Jak2V617F chimerism in the long-term HSC compartment (Jak2V617F chimerism Vehicle 41.4% vs. IFNα 23.9%, p&lt;0.05). IFNα treatment impaired the transmission of Jak2V617F-MPN and reduced Jak2V617F chimerism in transplanted recipient mice, demonstrating functional depletion of disease-specific stem cells.</jats:p> <jats:p>Mechanistically, IFNα treatment preferentially induced cell-cycle activation of Jak2V617F mutant long-term HSCs. Gene expression profiling revealed relative enrichment of cell cycle genes and depletion of quiescence related genes in IFNα treated Jak2V617F HSC compared to IFNα treated WT HSC. IFNα treatment promoted a predetermined terminal erythroid-lineage differentiation program within myeloid progenitor cells. The effects on Jak2V617F long-term HSC were absent in Jak2V617F+/−IFNAR1−/− (lacking the type 1 interferon receptor) chimeric mice demonstrating that the effects of IFNα treatment were cell autonomous and specific for type 1 interferon signalling.</jats:p> <jats:p>These findings provide insights into the differential effects of IFNα on Jak2V617F mutant and normal hematopoiesis and suggest that IFNα achieves molecular remissions in MPN patients through its effects on MPN stem cells. Furthermore, these results support combinatorial therapeutic approaches in MPN, by concurrently depleting dormant JAK2V617F MPN-propagating stem cells with IFNα and targeting the proliferating downstream progeny with JAK2-inhibitors or cytotoxic chemotherapy.</jats:p> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>Heidel: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees. Ebert:Celgene: Consultancy; Genoptix: Consultancy.</jats:p> </jats:sec> Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera Blood
spellingShingle Mullally, Ann, Bruedigam, Claudia, Heckl, Dirk, Poveromo, Luke, Heidel, Florian H., Hill, Geoff, Ebert, Benjamin L., Lane, Steven W., Blood, Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera, Cell Biology, Hematology, Immunology, Biochemistry
title Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera
title_full Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera
title_fullStr Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera
title_full_unstemmed Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera
title_short Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera
title_sort depletion of jak2v617f mpn stem cells by ifnα in a murine model of polycythemia vera
title_unstemmed Depletion of Jak2V617F MPN Stem Cells by IFNα in a Murine Model of Polycythemia Vera
topic Cell Biology, Hematology, Immunology, Biochemistry
url http://dx.doi.org/10.1182/blood.v120.21.806.806